BeiGene Price to Book Ratio 2014-2024 | ONC
Historical price to book ratio values for BeiGene (ONC) over the last 10 years. The current price to book ratio for BeiGene as of January 03, 2025 is 5.21.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| BeiGene Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2025-01-03 |
180.82 |
|
5.61 |
| 2024-09-30 |
224.51 |
$32.23 |
6.97 |
| 2024-06-30 |
142.67 |
$31.73 |
4.50 |
| 2024-03-31 |
156.39 |
$32.13 |
4.87 |
| 2023-12-31 |
180.36 |
$33.82 |
5.33 |
| 2023-09-30 |
179.87 |
$36.16 |
4.97 |
| 2023-06-30 |
178.30 |
$35.88 |
4.97 |
| 2023-03-31 |
215.53 |
$39.66 |
5.43 |
| 2022-12-31 |
219.94 |
$42.02 |
5.23 |
| 2022-09-30 |
134.82 |
$44.84 |
3.01 |
| 2022-06-30 |
161.85 |
$51.08 |
3.17 |
| 2022-03-31 |
188.60 |
$57.32 |
3.29 |
| 2021-12-31 |
270.93 |
$59.73 |
4.54 |
| 2021-09-30 |
363.00 |
$35.97 |
10.09 |
| 2021-06-30 |
343.19 |
$38.93 |
8.82 |
| 2021-03-31 |
348.08 |
$43.47 |
8.01 |
| 2020-12-31 |
258.39 |
$42.24 |
6.12 |
| 2020-09-30 |
286.44 |
$47.22 |
6.07 |
| 2020-06-30 |
188.40 |
$32.62 |
5.78 |
| 2020-03-31 |
123.11 |
$36.46 |
3.38 |
| 2019-12-31 |
165.76 |
$15.87 |
10.44 |
| 2019-09-30 |
122.46 |
$21.45 |
5.71 |
| 2019-06-30 |
123.95 |
$26.04 |
4.76 |
| 2019-03-31 |
132.00 |
$27.13 |
4.86 |
| 2018-12-31 |
140.26 |
$29.37 |
4.78 |
| 2018-09-30 |
172.22 |
$33.44 |
5.15 |
| 2018-06-30 |
153.73 |
$22.73 |
6.76 |
| 2018-03-31 |
168.00 |
$25.27 |
6.65 |
| 2017-12-31 |
97.72 |
$15.02 |
6.50 |
| 2017-09-30 |
103.46 |
$16.85 |
6.14 |
| 2017-06-30 |
45.00 |
$6.77 |
6.65 |
| 2017-03-31 |
36.61 |
$7.73 |
4.74 |
| 2016-12-31 |
30.36 |
$8.89 |
3.41 |
| 2016-09-30 |
30.81 |
$5.70 |
5.41 |
| 2016-06-30 |
29.80 |
$6.68 |
4.46 |
| 2016-03-31 |
29.31 |
$7.39 |
3.96 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
